Results 51 to 60 of about 261,105 (346)

Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis

Cancer immunology research, 2020
The standard of care for ovarian cancer has remained unchanged for almost 30 years, thus understanding the therapeutic mechanism of action might improve future therapeutic options.
T. Lau, L. Chan, G. C. Man, C. Wong, J. H. Lee, S. Yim, T. Cheung, I. McNeish, J. Kwong   +8 more
semanticscholar   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

PLoS ONE, 2021
Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory ...
J. Robert McCorkle, Justin W. Gorski, Jinpeng Liu, McKayla B. Riggs, Anthony B. McDowell, Nan Lin, Chi Wang, Frederick R. Ueland, Jill M. Kolesar   +8 more
doaj   +2 more sources

Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy

Nature Communications, 2020
Paclitaxel is widely used in cancer treatments, but poor water-solubility and toxicity raise serious concerns. Here we report an RNA four-way junction nanoparticle with ultra-thermodynamic stability to solubilize and load paclitaxel for targeted cancer ...
Sijin Guo, Mario Vieweger, Kaiming Zhang, Hongran Yin, Hongzhi Wang, Xin Li, Shanshan Li, Shuiying Hu, A. Sparreboom, B. Evers, Yizhou Dong, Wah Chiu, Wah Chiu, Peixuan Guo   +13 more
semanticscholar   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients

Frontiers in Pharmacology, 2018
Objective: The aim of this study was to explore the tolerance, variability, and pharmacokinetics (PK) of albumin-bound paclitaxel (QL, HR, ZDTQ) among Chinese breast cancer patients.Methods: Three randomized, open-label, two-period crossover ...
Qingmei Li, Hong Zhang, Xiaoxue Zhu, Chengjiao Liu, Min Wu, Cuiyun Li, Xiaojiao Li, Lei Gao, Yanhua Ding   +8 more
doaj   +1 more source

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Journal of Clinical Oncology, 2018
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous ...
A. Fader, D. Roque, E. Siegel, N. Buza, P. Hui, O. Abdelghany, S. Chambers, A. Secord, L. Havrilesky, D. O’Malley, F. Backes, N. Nevadunsky, B. Edraki, D. Pikaart, W. Lowery, K. ElSahwi, P. Celano, S. Bellone, M. Azodi, B. Litkouhi, E. Ratner, D. Silasi, P. Schwartz, A. Santin   +23 more
semanticscholar   +1 more source

International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.

Journal of Clinical Oncology, 2020
PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen.
S. Rao, Francesco Sclafani, Cathy Eng, R. Adams, M. Guren, David Sebag-Montefiore, Al B. Benson, A. Bryant, C. Peckitt, E. Segelov, Amitesh Roy, M. Seymour, Jack Welch, Mark Saunders, R. Muirhead, Peter O'Dwyer, J. Bridgewater, Shree Bhide, Rob Glynne-Jones, Dirk Arnold, David Cunningham   +20 more
semanticscholar   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Intravitreal Ranibizumab Had Limited Effect on Cystoid Macular Edema Due to Albumin-Bound Paclitaxel: A Case Report and Literature Review

Frontiers in Oncology, 2021
Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel).
Suna Ye, Suna Ye, Qiqi Fang, Jinyu Yao, Jianqiang Xing, Shibo Tang, Shibo Tang, Jacey Hongjie Ma, Jacey Hongjie Ma   +8 more
doaj   +1 more source